Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and community based cancer medical center – provided their perspectives on how they approach the challenge of addressing this need. The speakers will present on the reasons why they chose to internalize NGS testing, the value it brings to their healthcare system/network and what was involved to actualize their programs. Digital analytics and analysis employed by LTS Health was incorporated to provide feedback on the impact to laboratory operations and forecasting for future growth.
1. Recognize the biomarkers that prompt the need for a multi-gene panel to maximize testing results from a single tissue biopsy.
2. List the attributes of a Comprehensive Genomics Panel that would be used to drive personalized medicine testing using NGS (next-generation sequencing).
3. Describe the Molecular Tumor Board considerations when doing case reviews.
4. Identify the components of a Quality Management System for NGS (next-generation sequencing) workflows.